Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Louise Chen
SCOT
Louise Chen
Wall Street Analyst
★☆☆☆☆
#2506
on 13Foresight · ranked by our own returns
41%
Success Rate
+1.7%
Average Return
28 of 69 calls profitable · -11.3% vs benchmark
📈 Across the calls we could measure, roughly 41% of Louise Chen's ratings turned a profit when each position was held for 1 year — averaging +1.7% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

99 Buy 25 Hold 0 Sell
Louise's Stock Coverage 71 ratings · 2026-06-19
Company Date Position Consensus Price Target 1-Yr Return
GILD
Gilead Sciences
Jun 18, 2026 BUY Strong Buy
-4.8% avg upside
66 analysts
$177.00
42.95% Upside
+0.0%
TEVA
Teva Pharmaceutical
Jun 15, 2026 BUY Buy
-6.8% avg upside
39 analysts
$40.00
27.10% Upside
-3.4%
JNJ
Johnson & Johnson
Jun 09, 2026 BUY Strong Buy
-3.6% avg upside
36 analysts
$265.00
16.00% Upside
-0.8%
MRK
Merck & Company
Jun 02, 2026 BUY Strong Buy
+10.7% avg upside
43 analysts
$136.00
19.47% Upside
+0.5%
BMY
Bristol-Myers Squibb
Jun 01, 2026 HOLD Buy
+9.1% avg upside
42 analysts
$60.00
11.10% Upside
+0.6%
PFE
Pfizer
May 28, 2026 BUY Buy
+34.1% avg upside
45 analysts
$30.00
19.05% Upside
-3.6%
REGN
Regeneron
May 19, 2026 HOLD Strong Buy
+26.9% avg upside
57 analysts
$770.00
26.30% Upside
-3.4%
VRTX
Vertex Pharmaceuticals
May 05, 2026 BUY Strong Buy
-2.7% avg upside
61 analysts
$558.00
23.48% Upside
+8.2%
AMGN
Amgen
May 01, 2026 BUY Buy
-11.6% avg upside
57 analysts
$385.00
13.96% Upside
+6.3%
ABBV
AbbVie
Apr 30, 2026 BUY Buy
+2.8% avg upside
43 analysts
$280.00
29.38% Upside
+4.7%
LLY
Eli Lilly & Co
Apr 28, 2026 BUY Strong Buy
-10.5% avg upside
47 analysts
$1300.00
18.30% Upside
+25.9%
INVA
Innoviva
Aug 07, 2025 BUY Buy
+27.2% avg upside
12 analysts
$55.00
144.51% Upside
+22.6%
SRPT
Sarepta Therapeutics
Aug 07, 2025 BUY Buy
+246.5% avg upside
49 analysts
$80.00
356.34% Upside
-12.3%
COGT
Cogent Biosciences
Aug 06, 2025 BUY Strong Buy
+7.4% avg upside
26 analysts
$17.00
50.74% Downside
+212.0%
ARDX
Ardelyx
Aug 05, 2025 BUY Strong Buy
+124.7% avg upside
21 analysts
$15.00
147.94% Upside
+8.0%
ACRS
Aclaris Therapeutics
Jul 30, 2025 BUY Strong Buy
+122.9% avg upside
15 analysts
$9.00
99.95% Upside
+182.3%
DYN
Dyne Therapeutics
Jul 29, 2025 BUY Strong Buy
+93.5% avg upside
29 analysts
$50.00
152.60% Upside
+115.2%
PTCT
PTC Therapeutics
Jul 29, 2025 HOLD Buy
-1.4% avg upside
29 analysts
$55.00
30.27% Downside
+59.3%
PVLA
Palvella Therapeutics
Jul 22, 2025 BUY Strong Buy
+45.4% avg upside
27 analysts
$50.00
55.86% Downside
+214.2%
CATX
Perspective Therapeutics
Jul 10, 2025 BUY Strong Buy
+278.9% avg upside
22 analysts
$15.00
408.48% Upside
-28.7%
GANX
Gain Therapeutics
Jul 09, 2025 BUY Strong Buy
+318.8% avg upside
9 analysts
$12.00
538.26% Upside
+1.1%
ZLAB
Zai Lab
Jul 02, 2025 BUY Strong Buy
+223.0% avg upside
13 analysts
$55.00
202.46% Upside
-51.9%
EWTX
Edgewise Therapeutics
Jun 27, 2025 HOLD Strong Buy
+22.4% avg upside
14 analysts
$14.00
62.03% Downside
+157.8%
SPRY
ARS Pharmaceuticals
May 15, 2025 BUY Strong Buy
+121.7% avg upside
12 analysts
$30.00
210.81% Upside
-39.1%
PCVX
Vaxcyte
Jan 28, 2025 HOLD Strong Buy
+96.3% avg upside
15 analysts
-44.2%
NVO
Novo Nordisk
Jan 28, 2025 HOLD Buy
+168.1% avg upside
26 analysts
-27.2%
ATOS
Atossa Therapeutics
Jan 03, 2025 HOLD Strong Buy
+870.1% avg upside
6 analysts
-37.6%
ANL
Adlai Nortye Ltd. Sponsored ADR
Jan 03, 2025 HOLD Strong Buy
+113.6% avg upside
6 analysts
-40.0%
LYRA
Lyra Therapeutics
Jan 03, 2025 HOLD Hold
+3282.4% avg upside
7 analysts
-69.6%
SPRO
Spero Therapeutics
Jan 03, 2025 HOLD Buy
+501.5% avg upside
12 analysts
+113.6%
PDSB
PDS Biotechnology
Jan 03, 2025 HOLD Strong Buy
+1493.1% avg upside
11 analysts
-53.7%
SCYX
SCYNEXIS
Jan 03, 2025 HOLD Strong Buy
+225.1% avg upside
10 analysts
-54.6%
ONCY
Oncolytics Biotech
Jan 03, 2025 HOLD Strong Buy
+654.5% avg upside
12 analysts
+2.1%
ZVRA
Zevra Therapeutics
Jun 10, 2024 BUY Strong Buy
+85.5% avg upside
15 analysts
+100.0%
ROIV
Roivant Sciences
May 30, 2024 BUY Strong Buy
+2.5% avg upside
17 analysts
+5.8%
EOLS
Evolus
Jan 16, 2024 BUY Strong Buy
+116.3% avg upside
9 analysts
+1.7%
IMVT
Immunovant
Oct 16, 2023 BUY Strong Buy
+9.0% avg upside
24 analysts
$45.00
27.29% Upside
-22.7%
MESO
Mesoblast
Aug 30, 2023 BUY Strong Buy
+73.3% avg upside
14 analysts
$34.00
136.58% Upside
+135.7%
TXMD
TherapeuticsMD
Aug 16, 2023 HOLD Buy
+220.5% avg upside
8 analysts
$5.00
156.39% Upside
-54.6%
CH:BSLN
Basilea Pharmaceutica
Aug 15, 2023 BUY Strong Buy
+44.2% avg upside
6 analysts
$73.00
44.05% Upside
·
EFTR
eFFECTOR Therapeutics
Aug 08, 2023 BUY Strong Buy
+66249899.9% avg upside
5 analysts
$250.00
124999899.90% Upside
-99.7%
ARQT
Arcutis Biotherapeutics
Aug 08, 2023 BUY Strong Buy
+49.8% avg upside
14 analysts
$50.00
90.69% Upside
-9.0%
HCM
HUTCHMED
Jul 24, 2023 BUY Strong Buy
+208.7% avg upside
9 analysts
$50.00
386.35% Upside
+38.6%
AMRN
Amarin
Jul 18, 2023 BUY Buy
-47.2% avg upside
18 analysts
$5.00
68.79% Downside
-44.8%
NBP
NovaBridge Biosciences
Jul 06, 2023 BUY Strong Buy
+1306.0% avg upside
14 analysts
$25.00
1566.62% Upside
·
VYNE
VYNE Therapeutics
May 12, 2023 BUY Strong Buy
+2024.6% avg upside
9 analysts
$9.00
1316.36% Upside
-63.1%
CFRXQ
ContraFect
Mar 17, 2023 HOLD Buy
+10969999900.0% avg upside
10 analysts
·
AVTX
Avalo Therapeutics
Feb 13, 2023 HOLD Strong Buy
+265.1% avg upside
19 analysts
-99.3%
ZTS
Zoetis
Nov 03, 2022 BUY Buy
+71.4% avg upside
22 analysts
$250.00
217.57% Upside
+24.8%
CNTB
Connect Biopharma Holdings
Jun 02, 2022 BUY Strong Buy
+226.3% avg upside
11 analysts
$5.00
150.06% Upside
+54.4%
ARDS
Aridis Pharmaceuticals
Dec 21, 2021 BUY Strong Buy
+427319.4% avg upside
5 analysts
$18.00
580545.18% Upside
-62.9%
RVLPQ
RVL Pharmaceuticals
Sep 24, 2021 BUY Strong Buy
+624999900.0% avg upside
6 analysts
$6.00
599999900.01% Upside
-22.9%
JAGX
Jaguar Animal Health
Sep 20, 2021 BUY Strong Buy
+108.3% avg upside
5 analysts
$5.00
122.15% Upside
-91.6%
EVFM
Evofem Biosciences
May 26, 2020 BUY Buy
+269017.6% avg upside
8 analysts
$15.00
176370.50% Upside
·
DE:MRK
Merck KGaA
Apr 29, 2020 BUY Buy
+2.1% avg upside
32 analysts
$93.36
29.92% Downside
·
VTRS
Viatris
Mar 25, 2020 HOLD Buy
+48.2% avg upside
21 analysts
$22.00
43.23% Upside
-6.8%
TBPH
Theravance Biopharma
Feb 25, 2020 BUY Buy
+12.2% avg upside
18 analysts
$55.00
231.77% Upside
-24.9%
PRGO
Perrigo Company
Jan 21, 2020 BUY Buy
+565.5% avg upside
20 analysts
$70.00
582.94% Upside
-26.2%
TSE:BHC
Bausch Health Companies
Jan 09, 2020 BUY Buy
+783.6% avg upside
29 analysts
$50.92
655.58% Upside
·
FR:ALCOX
Nicox SA
Dec 16, 2019 BUY Strong Buy
+1599.7% avg upside
5 analysts
$12.00
3025.00% Upside
·
ALDX
Aldeyra Therapeutics
Oct 22, 2019 BUY Strong Buy
+716.1% avg upside
21 analysts
$33.00
1583.67% Upside
+27.4%
AMRX
Amneal Pharmaceuticals
May 09, 2019 BUY Strong Buy
+5.6% avg upside
18 analysts
$35.00
115.95% Upside
-67.8%
OPK
Opko Health
Nov 09, 2018 BUY Strong Buy
+374.3% avg upside
12 analysts
$20.00
1308.50% Upside
-52.4%
HRTX
Heron Therapeutics
Sep 27, 2018 BUY Strong Buy
+6439.5% avg upside
21 analysts
$50.00
11876.12% Upside
-37.5%
TLPH
Talphera
Sep 25, 2018 BUY Buy
+339.6% avg upside
15 analysts
-44.8%
NBRVF
Nabriva Therapeutics
Jul 24, 2018 BUY Buy
+13374900.0% avg upside
9 analysts
$16.00
15999899.98% Upside
·
XFOR
X4 Pharmaceuticals
Jun 28, 2018 BUY Strong Buy
+496.4% avg upside
15 analysts
$26.00
516.06% Upside
-37.5%
JAZZ
Jazz Pharmaceuticals
Apr 06, 2017 BUY Strong Buy
-1.8% avg upside
35 analysts
-2.6%
ANIP
ANI Pharmaceuticals
Apr 05, 2017 BUY Strong Buy
+28.6% avg upside
11 analysts
$80.00
0.54% Upside
+22.9%
XENE
Xenon
Sep 26, 2016 BUY Strong Buy
+19.0% avg upside
28 analysts
$20.00
62.15% Downside
·
PAHC
Phibro Animal Health
Jun 24, 2015 BUY Hold
+17.0% avg upside
10 analysts
$45.00
41.37% Upside
-47.3%
🔒 66 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Louise Chen — Frequently Asked Questions
How accurate are Louise Chen's stock ratings?
Based on the calls 13Foresight could measure, about 41% of Louise's ratings were profitable over a one-year hold, with an average return of +1.7% per rating, or -11.3% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Louise ranked on 13Foresight?
Louise Chen is currently ranked #2506 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Louise cover?
Louise most recently has ratings on GILD, TEVA, JNJ, MRK, BMY, PFE, REGN, VRTX, AMGN, ABBV, LLY, INVA and 59 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.